Novo Nordisk's Wegovy pill leads obesity treatment, challenging Eli Lilly with superior efficacy and fewer restrictions.
Novo Nordisk has regained competitive ground in the obesity market with the strong launch of its Wegovy pill, which outperforms Eli Lilly's Foundayo in new prescriptions due to better weight loss results and fewer drug interaction limits. Despite rec...
